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Acetylation, Deacetylation and
Acyltransfer
by Charles M. King* and Irene B. Glowinskit
N-Substituted aromatic compounds can be metabolized in most species to N-acetylated derivatives
that are themselves subject to further enzymatic transformations, including hydrolysis and N,O-
acyltransfer. These proceses can either potentiate or ameliorate the biological responses to these N-
substituted derivatives. Decreasing the levels of metabolites, such as arylhydroxylamines may, in
some systems, reduce the probability of eliciting adverse biological effects. In others, arylhydroxamic
acids produced by the acetylation of arylhydroxylamines may increase their potential for metabolic
activation byN,O-acyltransfer. In the rabbit, rat and perhaps other species, the acetyl CoA-dependent
N-acetyltransferase is also capable of activating arylhydroxamic acids byN-O-acyltransfer. These cy-
tosolic organotriphosphate ester-resistant enzymes can utilize arylhydroxamic acid as a donor of the
acetyl moiety in the acetyl transferase reaction and apparently are capable of activating arylhydrox-
amic acids because of their ability to O-acetylate the arylhydroxlamine. In mice,N-acetyltransferase
and N,O-acetyltransferase seem not to exhibit this relationship. Enzymes from the microsomes of a
number of species are also capable of activating arylhydroxamic acids. The particulate-bound en-
zymes are organotriphosphate ester-sensitive deacylases that are unable to form nucleic acid adducts
on incubation with N-methoxy-N-acetylaminoarenes, substrates that are not capable of activation by
N,O-acyltransfer. Thus, depending on the specificity of the enzymes involved, N-substituted aro-
matic compounds may be activated by N,O-acyltransfer during both the acetylation and deacylation
process. The influence of this activation in the carcinogenic process is the object of continuing in-
vestigation.
Introduction
N-Substituted aromatic compounds are subject to
enzymatic N-acetylation and further metabolism of
the N-acetylated derivatives. Interest in the forma-
tion and disposition of these compounds comes from
recognition that metabolism may modify the biologi-
cal response to these agents by serving to reduce
the levels of metabolites with undesirable proper-
ties (e.g., arylhydroxylamines) or to provide sub-
strates (e.g., arylhydroxamic acids) for metabolic
pathways which generate products that can ad-
versely affect biological systems. Although meta-
bolic oxidation of the methyl group of the N-acetyl
moiety does occur, this pathway will not be ad-
dressed here, since the glycolamide does not appear
to be involved in the tumorigenicity of arylamines
(1). The purpose of this communication is to relate
recent progress in our understanding of the interre-
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lationships between N-acetylation, arylhydroxamic
acid N,O-acyltransfer and deacetylation of N-substi-
tuted compounds, as these three reactions are
capable of producing carcinogenic and mutagenic
aromatic amine derivatives.
MAcetylation
Mechanism of Action and Distribution
N-Acetylation of aromatic amine carcinogens was
first observed in rat liver slices using aminofluorene
as substrate (2) (Fig. 1). Subsequent studies showed
that other species were also capable of N-acetyl-
ating 2-aminofluorene (AF) as well as 4-aminobiphe-
nyl and 2-naphthylamine (3, 4). The enzyme respon-
sible for this metabolic step, acetyl CoA-dependent
N-acetyltransferase (NAT), is the same enzyme as
that responsible for the N-acetylation of aromatic
amine drugs such as isoniazid and sulfamethazine
(5). This is important in that Poirier et al. (6) postu-
lated that N-arylhydroxylamines were involved in
bladder cancer induction, whereas the acetylated
derivatives were required for carcinogenesis in
liver. The dog, unable to acetylate aromatic aminesKING AND GLOWINSKI
N-Acety/ation
NH
N,0-Acy/transfer
0
.,C-R'
Deacy/ation
0
IIC-
'.
aNoC-H0
0 ~N"'C-CH3
- N* N O-C-R'
11
0
- C~~~H
the incidence of toxic responses (12, 13). Similarly, it
is possible that the capacity for N-acetylation may
regulate both the occurrence of tumors in specific
organs and the susceptibility to carcinogenesis from
aromatic amines. Lower (14) has suggested a pos-
sible correlation between acetylator phenotype and
urinary bladder cancer induction. Studies to deter-
mine if such a correlation exists are now in progress
(15).
In addition to the human polymorphism, large ge-
netic variation in N-acetylation of both aromatic
amine drugs and carcinogens is also observed in
rabbit (5). A comparative study of the capacity of
rabbit liver to carry out N-acetylation and to acti-
vate arylhydroxamic acids by N,O-acyltransfer (Fig.
1) revealed large genetic variations in both enzymes
in this species (Table 1). Thus, both acetyl transfer
Where R - -H or -OH
R' - -H, -CH3, -CH2CH3, etC.
FIGURE 1. Metabolism ofN-acyl substituents.
(4), is still susceptible to bladder cancer by these
compounds and recent work has shown that this
process is probably mediated by the N-glucuronide
of the N-arylhydroxylamine (7, 8).
NAT is a cytosolic enzyme found in many tissues
of a number of species. In the rabbit, greater than
80% of the total acetylating capacity of the animal
is in the liver and gut. Low yet detectable levels
have been found in blood, brain, kidney, lung,
spleen, testes and thymus of this species (9). Liver
cytosols of hamster, guinea pig, mouse, rat and man
are also capable of N-acetylating carcinogenic aryla-
mines such as AF, 4-aminobiphenyl and 2-naphthyla-
mine (4, 10). Recent studies in inbred mice have
shown that in the A/J and C57BL/6J strains, small
intestine, kidney and blood, as well as liver, are ca-
pable ofN-acetylating AF and benzidine (11). In rab
bit, the NAT of liver and gut reflects a genetic poly-
morphism (see below) that is not evident in kidney
and spleen (9). In contrast, blood, liver, kidney and
small intestine reflect the animal's phenotype in in-
bred mice (11).
Genetic Regulation
One of the most interesting aspects of N-acetyla-
tion in man is the existence of a hereditary polymor-
phism in the rate of this reaction. As a consequence,
persons are classified as either rapid or slow acetyl-
ators of certain arylamine drugs and carcinogens (5).
With respect to drugs such as isoniazid, these ge-
netic differences in the rate ofN-acetylation play an
important role in determining the variability seen in
Table 1. Liver NAT and AHAT from rabbits of specified
acetylator phenotype.a
Rabbit AHAT, NAT,
phenotypeb nmole/min/mg nmole/min/mg
Rapid
(RR) 0.802 1.74
(RR) 0.626 2.64
(RR) 0.343 3.20
(RR) 0.330 3.33
(Rr) 0.669 3.65
Slow
(rr) 0.00040 0.075
(rr) 0.00033 -
(rr) 0.00021 0.071
aEnzyme activities were determined in rabbit liver cytosol
with the use ofN-hydroxy-AAF or AF as substrates (16).
bRabbits were classified according to their arylamine
acetylator phenotype: RR = homozygous rapid acetylator; Rr
= heterozygous rapid acetylator; rr = slow acetylator
steps in the biotransformation of arylamines are
under common genetic control in rabbit liver. Fur-
ther studies showed that the two enzyme activities
could not be resolved by protein purification tech-
niques which exploited differences in solubility,
charge and size. In addition, both enzymes migrated
as a single symmetrical protein band after polya-
crylamide gel electrophoresis and both had the
same molecular weight (33,000) as determined by
electrophoresis on SDS-polyacrylamide gels (16).
The relationship between NAT and arylhydroxamic
acid N,O-acyltransferase (AHAT) was further
strengthened by recognition that arylhydroxamic
acids could replace acetyl CoA as an acetyl donor
for NAT. Thus, with respect to function, rabbit liver
recognizes arylhydroxamic acids as the donor of
acetyl groups. The identity of NAT and AHAT has
not yet been established for other species.
Recent studies (10) have now shown that inbred
mouse strains also exhibit a genetic polymorphism
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in their capacity for N-acetylation of the arylamine
carcinogens aminofluorene and benzidine (Tables 2
and 3). Of 20 strains surveyed, three are classified
as slow acetylators (A/J, AHe/J and X/Gf) and 17 as
rapid acetylators based on either blood benzidine or
liver benzidine NAT activities (Table 2). The rapid
Table 2. NAT activities in liver and blood of inbred mouse
strains.a
Benzidine NAT activity,
nmole/min/mg
Strain Blood
A/J NDb
AHe/J ND
X/Gf ND
AuSsJ 0.019
Castaneous
ST/bJ
C57BL/6J 0.036
Molossinus
SF 0.033
SWR/J 0.040
129/SV
RF/J 0.039
RIII/2J
IsCam
SJL/J
Balb/cJ 0.060
C3H/HeJ 0.064
CBA/J 0.048
AKR/J 0.052
DBA/J 0.064
aFrom Glowinski and Weber (10).
bND, not detectable.
Liver
0.058
0.032
0.178
0.361
0.277
0.123
0.364
0.209
0.215
0.294
0.287
0.338
0.114
0.411
0.247
0.314
0.362
0.314
0.345
0.320
acetylator strains possessed approximately 10 times
greater liver benzidine NAT specific activity than
the slow acetylator strains. Intercross and back-
cross matings of A/J (slow acetylator) and C57BL/6J
(rapid acetylator) mice indicate that a single gene
with two major alleles is responsible for the differ-
ences in NAT activity in both tissues for benzidine
or AF (10). The analysis of recombinant inbred
strains derived from matings of A/J with C57BL/6J
mice (Table 3) supports this conclusion (10).
Studies of other mouse tissues showed that kid-
neys from these strains exhibited the genetic poly-
morphism in N-acetylation of AF, unlike the situa-
tion in rabbit. Interesting sex differences were ap-
parent in C57BL/6J mouse kidney with males exhib-
iting approximately 2- to 5-fold higher AF-NAT ac-
tivity than do females. Similar sex differences have
been observed in the mutagenic activation of AAF
by mouse kidney microsomes (17). Studies to deter-
mine if AHAT activity was genetically controlled in
a manner similar to that for NAT in inbred mice re-
vealed that this was not the case and that only mar-
ginal AHAT activity was detected (18).
Thus, it is clear that there are distinct species dif-
ferences between the mouse and rabbit models of
Table 3. Liver and blood AF NAT activities in A/J, C57BL/6J,
AC57F1 and A/JxC57BL/6J recombinant inbred mouse strains.a
AF NAT activity, nmole/min/mg
Mouse strain Liver Blood Genotypeb
A/J 0.134 <0.016 A
C57BL/6J 1.26 0.110 B
AC57F1 0.703 0.065
BXA-1 1.37 0.163 B
BXA-3 0.126 <0.016 A
BXA-6 0.120 <0.016 A
BXA-15 0.113 <0.016 A
AXB-2 1.31 0.206 B
AXB-3 0.060 <0.016 A
AXB-4 0.098 <0.016 A
AXB-5 1.10 0.165 B
AXB-6 1.24 0.162 B
AXB-9 0.168 <0.016 A
AXB-17 1.30 0.173 B
aFrom Glowinski and Weber (10).
bA, A/J; B, C56BL/6J.
N-acetylation in both substrate and tissue specific-
ity, as well as in the AHAT-mediated metabolic acti-
vation pathway for AF. Rapid and slow acetylator
rabbits that display large genetic differences in
AHAT activity and rapid and slow acetylator mice
that do not may both be helpful in studying the ef-
fect of acetylator phenotype on aromatic amine-
induced carcinogenesis.
N,O*Acyltransfer
Cytosolic AHAT
Incubation of arylhydroxamic acids with nucleic
acids and rat liver cytosol results in adduct forma-
tion with reaction at carbon-8 of guanine and loss of
the N-acetyl moiety (19-21). The metabolic pathway
responsible for this activation results from the for-
mation of reactive N-acyloxyarylamines (22, 23). The
instability of these metabolites has thus far pre-
cluded their direct synthesis. Evidence for their
metabolic formation has come from (1) the report
that the addition of arylhydroxylamine increases ad-
duct formation (22), (2) the inability of the enzyme to
activate N-methoxy-N-acetyl-2-aminofluorene (23),
and (3) the association of adduct formation with the
ability of the enzyme to transfer the N-acetyl moi-
ety of arylhydroxamic acids to primary arylamines
(22-24). This latter reaction, first described by Booth
(24), is analogous to the NAT pathway as the hy-
droxamic acid serves as acetyl donor to yield aryla-
cetamides. Thus, the association between NAT and
AHAT in the rabbit (Table 1), as noted above, ap-
pears to hold for the rat since both species can uti-
lize arylhydroxamic acids for the acetylation of pri-
mary arylamines although extreme genetic varia-
tion has not been observed in the rat(25).
AHAT is widely distributed, as detected by nu-
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Table 4. Relative cytosolic AHAT activities.a
AF (x 10-" mole) bound to tRNA on incubation with cytosol from various species
Guinea Dog and
Tissue Rat Hamster Rabbit pig Monkey Baboon Pig Human Mouse goat
Liver llib 278b 371 9 56 58 32 12 5b <2b
Kidney 29 11 4 12 <2 <2
Small intestine 36b 118b 43 12b 20 17 <2 <2
Colon 38 31 6 10 <2 5 <2 <2
Stomach 24b 36b 2 14 <2 <2 <2
Lung 13 18 3 3 <2 2 <2
Mammary gland lob
Zymbal's gland lob
Spleen 7 4 2 3 <2 <2 <2
Brain 3 6 2 4
Uterus lob
Bladder 20b
aThese data were obtained by use of standardized assay conditions (23, 25, 39, 40-42). The assay involved incubation of N-
hydroxy-AAF (0.042 Mmole) and tRNA (15 Aa,o units) with cytosol equivalent to 20 mg of tissue in pyrophosphate buffer (0.05M,
pH 7.0) at 370C for 20 min. (43).
bTissue in which AF derivatives most commonly induce tumors.
cleic acid adduct formation on incubation of sub-
strates with tissue cytosols (Table 4). Although ac-
tivity is usually greatest in liver, a wide variety of
other organs have demonstrable levels of AHAT.
Importantly, dog tissues have neither AHAT nor
NAT. Cytosolic AHATs with molecular weights of
approximately 28,000 to 33,000 daltons are inhibited
by reagents that react with sulfhydryl groups. Both
N-acetylated and N-propionylated arylhydroxyla-
mines can serve as substrates for the cytosolic
AHAT and these reactions are not affected by or-
ganophosphate esterase inhibitors; N-formylated de-
rivatives are poor substrates at best (1, 18, 26, 27).
Mono-, di- and tricyclic arylhydroxamic acids, in-
cluding derivatives of phenacetin, naphthalene, bi-
phenyl, stilbene, fluorene and phenanthrene, can
also serve as substrates such as phenacetin, the rats
of adduct formation are considerably less than those
for N-acetyltransfer as measured by the Booth as-
say (29).
Although cytosolic AHAT can transform its sub-
strate to products that are mutagenic for Salmo-
nella (28-30), it has been shown that the reactive
product of the AHAT reaction is not responsible for
this activity (26, 30). The mutagenicity may result
from small quantities of hydroxylamines produced
as a consequence of hydrolytic uncoupling of the
acyltransfer process.
Studies of the structure-activity relationships
have provided evidence that the organophosphate-
insensitive AHAT of mammary gland of Sprague-
Dawley derived female rats is involved in aryla-
mine-induced tumors in this organ. Giganti and her
colleagues have shown that direct treatment of the
mammary gland with the hydroxamic acid N-hy-
droxy-N-acetyl-2-aminofluorene (N-hydroxy-AAF) is
more effective in producing tumors than is the ad-
ministration of the hydroxylamine, nitroso or amide
derivatives (31). Subsequent experiments have em-
ployed arylhydroxamic acids that differ in their N-
acyl moieties and, consequently, differ in their po-
tential for activation by AHAT. The results suggest
that rat mammary gland tumor susceptibility is re-
lated to the ability of arylhydroxamic acids to serve
as substrates for AHAT, i.e., acetylated compounds
are more active than formylated compounds (1, 27,
32). While the evidence of a causal role for AHAT in
other tissues is less convincing, the major DNA ad-
ducts formed in all target tissues studied thus far
are compatible with their formation via an acyl-
transfer mechanism.
Microsomal AHAT
Recent observations have disclosed that liver mi-
crosomes from a number of species have the ability
to generate nucleic acid adducts on incubation with
arylhydroxamic acids (Table 5) (1, 18). This activity
yields arylamine-substituted guanine derivatives at
carbon-8 without retention of the acyl group to give
the same product as that produced by the cytosolic
acyltransferases. However, unlike the case for the
cytosolic enzymes, diethyl-p-nitrophenylphosphate
(Paraoxon) is a potent inhibitor of the microsome-
catalyzed activation. Resolution of solubilized gui-
nea pig liver microsome preparations disclosed that
two proteins are responsible for adduct formation
(Table 6). These enzymes are readily distinguishable
by differences in size and by their relative abilities
to hydrolyze arylhydroxamic acids and amides. Sub-
stitution of the acidic hydrogen of the hydroxamic
acid with a methyl group leads to reduction in ad-
duct formation and provides evidence for activation
by an acyltransfer mechanism (18).
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Table 5. Species variation in the deacylation and AHAT activities of liver microsomes.
Deacylase, nmole/min/mg proteina
With With
AHAT, nmole/min/mg proteina
With With
Species/strain N-Hydroxy-AAF N-Hydroxy-FAF N-Hydroxy-AAF N-Hydroxy-FAF
Guinea pig (11)b 59 31 0.01 0.32
Hamster (2) 14.3 4.8 0.45 0.26
Rabbitc
RR (1) 1.5 2.7 0.08 0.17
Rr (1) 3.9 5.0 0.09 0.18
rr (1) 7.5 11.6 0.14 0.64
Mouse
A/J (2) 3.4 3.7 0.02 0.09
C57BL/6J (2) 4.0 3.2 0.03 0.21
Dog (3) 2.3 1.5 0.003 0.05
Rat (3) 1.9 1.3 0.02 0.18
aMeans of the initial rates (18).
bThe number of animals employed are given in parentheses.
cRabbits were classified according to their arylamine acetylator phenotype (16): RR = homozygous rapid acetylator; Rr =
heterozygous rapid acetylator; rr = slow acetylator.
Table 6. Relationship of AHAT from cytosols and microsomes.
Enzyme source Type of AHATa
Rat
Liver cytosol hIF IIJAc
Liver microsomes hIF & Ac
Mammary gland cytosol hIF IIJAc
Guinea pig
Liver cytosol IF & Ac hIF IIJAc
Liver microsomes IF & Ac hIF & Ac
aThe AHATs are classified according to the resolution of
cytosols and solubilized microsomal preparations by gel
filtration on Sephacryl S-200. The relative elution volumes of
types I, II and III are 1.3 to 1.4, 1.55 to 1.65, and 1.8 to 1.9,
respectively. These values, which are inversely related to
molecular weight, are defined as the ratio of the volume
required for elution of the peak enzyme activity to the volume
at which excluded macromolecules first emerge from the
column. Rat liver AHAT migrates with an apparent molecular
weight of 28,000 on Sephadex G-100 (23). The AHAT activities
were detected by assay of nucleic acid adduct formation on
incubation with either the N-forymylated (F) or N-acetylated
(Ac) N-2-fluorenylhydroxylamine. Type I and II AHAT are
inhibited by diethyl-p-nitrophenylphosphate; Type III is
resistant to this organophosphate (1, 18).
Deacylation
Hydroxamic Acids
Both N-hydroxy-AAF (33, 34) and N-hydroxy-N-
formyl-2-aminofluorene (N-hydroxy-FAF) can be de-
acylated by enzymes present in the liver microso-
mal fractions of guinea pig, hamster, rabbit, mouse,
dog and rat (Table 5) to produce the hydroxylamine,
N-hydroxy-AF. As previously shown for N-hydroxy-
AAF (33), guinea pig possesses the highest micro-
somal deacylase activity. All species tested, except
guinea pig, have very low or nondetectable cytosolic
deacylase activity for N-hydroxy-AAF. In contrast,
N-hydroxy-FAF can be deacylated by cytosols of all
species except hamster.
Guinea pig liver microsomes contain two en-
zymes capable of these reactions that differ in mo-
lecular weight as demonstrated by gel filtration (18,
35). A wide range of acylated compounds are sub-
strates for both enzymes (35). With respect to aro-
matic amines, the larger enzyme hydrolyzes N-hy-
droxy-AAF approximately 200 times faster than
N-acetyl-2-aminofluorene (AAF), whereas the activi-
ties for hydrolysis of both compounds are about the
same with the smaller enzyme (18, 35). Recent work
has shown that these purified microsomal deacyl-
ases are also capable of transforming N-hydroxy-
AAF and N-hydroxy-FAF to derivatives that are
capable of reacting with nucleic acid (see above).
Both enzymes are inhibited by paraoxon. Guinea pig
liver microsomes are also capable of deacetylating
the O-glucuronide of N-hydroxy-AAF to yield me-
tabolites that react with nucleic acids (36).
Jarvinen et al. (35) showed that in addition to mi-
crosomes from guinea pig liver, other tissues such
as kidney and brain contain N-hydroxy-AAF de-
acylase activity. In an extensive survey of rat tis-
sues, Irving (37) demonstrated that by far the high-
est N-hydroxy-AAF deacylation in this species oc-
curs in the Zymbal's gland, an organ that is highly
susceptible to carcinogenesis by AAF, N-hydroxy-
AAF and other aromatic amines and amides. In con-
trast, the mammary gland, another rat tissue highly
susceptible to carcinogenesis from these com-
pounds, has very low deacylase activity.
Amides
Liver microsomes of many species also possess
the ability to deacylate carcinogenic arylacetamides.
Lower (34) showed that this is both substrate- and
species-specific. Hamster and dog have relatively
good activity for the deacylation of acetylaminobi-48 KING AND GLOWINSKI
phenyl and acetylaminofluorene; mouse has very
high activity for acetylaminobiphenyl deacylation;
and rat and guinea pig have very low activities for
both. We have recently shown that guinea pig liver
microsomes are also capable of deacylating N-for-
myl-2-aminofluorene as well as AAF (18). In addition
to rat liver, rat intestine, a target organ for AAF-in-
duced tumorigenesis, is capable of deacylating AAF
as well as other acylaminofluorenes (38).
Relationship of N-Acetylation, N,O*
Acyltransfer and Deacylation
As noted above, NAT and AHAT activities are
identical in rabbit, but may not be related in mouse.
While definitive experiments have not been carried
out in rat, the association of cytosolic AHAT with
the ability of arylhydroxamic acids to serve as ace-
tyl donors in this species suggests that such a rela-
tionship does exist. It is probable that evolutionary
changes have resulted in the development of a
series of related NATs that differ both in their abili-
ties to utilize hydroxamic acids as acetyl donors,
and in their abilities to transfer the putative NAT-
bound acyl group to the oxygen of the hydroxyla-
mine, to produce a reactiveN-acyloxyarylamine.
Recognition of the presence of other AHATs that
are unrelated to the NAT enzymes came from ex-
periments in which N-formylated hydroxamic acids
were used to induce mammary gland tumors (1, 27).
These studies identified a rat cytosolic enzyme that
was capable of transforming N-formyl, but not N-
acetyl or N-propionyl, derivatives to reactive prod-
ucts. The enzyme that activated the formyl com-
pounds differed from the previously studied enzyme
in that it was larger and was inhibited by diethyl-p-
nitrophenylphosphate. Inhibition by an organophos-
phate prompted experiments to examine the
possibility that this enzyme was a microsomal de-
acylaselike component that had been solubilized
during the homogenization procedure (18). These ef-
forts produced evidence (Table 6) that the organo-
phosphate-sensitive enzyme had been released from
microsomes with a concomitant loss of ability to ac-
tivate N-acetylated derivatives. Similar experi-
ments with guinea pig liver preparations demon-
strated that the two microsomal AHATs of this
organ also appear in cytosol. The sizes, sensitivities
to inhibitors, and structure-activity relationships of
these enzymes support the conclusion that micro-
somal deacylases can activate arylhydroxamic acids
by N,O-acyltransfer. The great species variation in
the structure-activity relationships of liver micro-
somal AHATs and deacylases suggests that evolu-
tion has resulted in families of enzymes that are
analogous to those of NAT.
The presence of both deacylase and AHAT activi-
ties in the same enzyme preparation raises the
question of the relative contributions of these two
pathways to nucleic acid adduct formation. In rat
microsomes, the rate of adduct formation after N-
hydroxy-FAF metabolism is only 14% that of hy-
droxylamine formation (Table 5). However, in guin-
ea pig liver microsomes, adduct formation after N-
hydroxy-AAF metabolism is less than 0.02% that of
the rate of hydrolysis, and most of the adduct for-
mation potential is chromatographically separable
from the deacylase activity. These data suggest
that, while reaction of arylhydroxylamines with nu-
cleic acid can occur at neutral pH, adduct formation
in these enzyme-mediated systems occurs primarily
as a consequence of the formation of products that
are more reactive than the hydroxylamine. How-
ever, based on the results of studies with cytosolic
AHAT, mutagenicity in Salmonella would be ex-
pected to be more influenced by hydroxylamine pro-
duction than by the potential for adduct formation
in cell-free systems. It is hoped that recognition of
the relationship of these three metabolic pathways
will be of aid in better defining their role in the in-
duction of tumors by arylamines.
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